Somatostatin receptor scintigraphy: the definitive technique for characterizing vasoactive intestinal peptide-secreting tumors.
Vasoactive intestinal peptide-secreting tumors (VIPomas) are extremely rare and difficult to diagnose. The authors describe a patient who was found to have a VIPoma after 3 years of symptoms. Somatostatin receptor scintigraphy using indium-labeled octreotide localized her tumor and prompted a surgical resection. This is the preferred imaging study for the earliest, most accurate, and cost-effective identification of VIPomas and their metastases.
Thomason
J W
JW
Department of Medicine, Medical College of Georgia, Augusta, USA. jthomaso@mail.mcg.edu
Martin
R S
RS
Fincher
M E
ME
D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D015282:Octreotide; D015609:Organotechnetium Compounds; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin / Q000378:metabolism*; D014057:Tomography, X-Ray Computed; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism*
D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C120319:technetium Tc 99m cyclopentadienyltricarbonyloctreotide; D014660:Vasoactive Intestinal Peptide; D015282:Octreotide